GlobeNewswire by notified

Park Place Technologies Acquires Unitech’s Third Party Maintenance Services

Share

Deal forms one of Brazil’s largest TPM providers.

CLEVELAND, OH, April 30, 2024 (GLOBE NEWSWIRE) -- Park Place Technologies, a leading global provider of data center and networking optimization solutions, has acquired Unitech's third-party maintenance (TPM) business. The acquisition strengthens Park Place's position as one of Brazil's largest TPM providers, expanding its reach in the world's fifth-largest country.

Combined Expertise for Enhanced Customer Service

Unitech, founded in 1989, has a long-standing reputation for serving a diverse client base, including major financial institutions, telecommunication and utility companies. Park Place's global expertise will greatly amplify Unitech's established presence in the Brazil market.

“Unitech and Park Place serve clients with the same core values. We both operate with a responsive, client-first approach, and communicate with clarity and transparency. We share customer service strategies, and have a native understanding of the Brazil TPM market,” said Unitech owner Ramon Hasky.

Hasky said Unitech’s long-term partnership with Park Place, “gives us confidence in how our clients will now be served. Park Place is a global company with a strong Latin American presence that offers more scale and an innovative IT lifecycle portfolio. Our customers will benefit from these added Managed Services and Professional Services offerings.”

Park Place, now one of Brazil’s furthest-reaching TPMs, will add nearly 20,000 Unitech assets to its already robust service legacy in Brazil.

“We are taking the hard-earned credibility of Unitech’s 30-plus years and leveraging our passion for client services with Park Place’s global resources,” said Unitech’s CEO, Claudio Miranda. “Unitech’s legacy now has an exciting new chapter; our people and our clients are in good hands with Park Place.”

Unitech will continue to independently operate its Hardware, Software and related Professional Services sales.

“Park Place operates in Brazil primarily in markets with a history of great relevance and positive expectations, particularly in the management, maintenance, and support of mission-critical hardware,” Luiz Fernando Monteiro, IDC Senior Market Analyst, IT Services, Brazil, said. “It is an operation focused on service lines that account for about 19% of the total service market in the country. These are essential services, especially in a world of IT distributed across internal infrastructures, own and third-party Data Centers, public and private clouds, with a demand for very high availability and resilience for the continuity of operations of companies across the entire Brazilian market.”

Roy Illsley, Chief Analyst for Omdia, said Omdia's research shows that Brazil is a rapidly growing market for the data center business. “In fact, São Paulo accounts for 85% of new Data Center building in the country,” he said. “However, the current Data Center market in Brazil is mostly small sized Data Centers that are distributed between the major cities. Brazil, represents an ideal market for a vendor like Park Place as the growth in data centers will need skills to ensure they can operate efficiently and effectively, and technology vendors with services and solutions are a perfect fit.”

Chris Adams, Park Place Technologies President and CEO, said the company’s history of investing in people and resources globally will continue.

“We are committed to delivering a great experience to all our customers worldwide,” he said. “We will continue to acquire companies like Unitech that bring a talented workforce and unique capabilities driven by an unparalleled customer experience to our international partners.”

A video statement from Unitech is available here.

About Park Place Technologies

Park Place Technologies is a global data center and networking optimization firm. We help more than 21,000 clients optimize data center budgets, productivity, performance, and sustainability so they can think bigger – and act faster. From procurement to decommissioning, our comprehensive portfolio of services and products helps IT teams optimize IT lifecycle management. This frees time and spend so they can focus on transforming their businesses for the future. 

Park Place’s industry-leading and award-winning services portfolio includes Park Place Hardware Maintenance™, Park Place Professional Services™, ParkView Managed Services™, Entuity Software ™ and Curvature Hardware sales. For more information, visit www.parkplacetechnologies.com. Park Place is a portfolio company of Charlesbank Capital Partners and GTCR.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.21.5.2024 02:25:00 CEST | Press release

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ— Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Hu

IDEX Biometrics – Number of shares in Tranche 1 vs Tranche 2 in the private placement on 15 May 202420.5.2024 23:52:54 CEST | Press release

Reference is made to the stock exchange announcement by IDEX Biometrics ASA (the “Company”) on 15 May 2024 regarding a successful private placement of shares. By inadvertence, the announcement contained a slight error in the allocation of private placement shares between Tranche 1, as issued by the Board pursuant to an authorization to issue shares granted by the extraordinary general meeting dated 21 December 2023, and Tranche 2, to be issued subject to approval by an extraordinary general meeting to be called and scheduled for on or about 12 June 2024. The correct number of Tranche 1 shares is 27,940,213, and the correct number of Tranche 2 shares is 5,393,120, each having a par value of NOK 0.15, with a subscription price of NOK 1.65 per share in the private placement. Consequently, following the issuance of Tranche 1 shares, the Company's share capital is increased with NOK 4,191,031.95 from NOK 42,018,983.25 to NOK 46,210,015.20, and the Company will have 308,066,768 shares issued

INVNT™ ANNOUNCED AS SPONSOR AND CO-PRODUCER OF DISCOVERY STAGE AT SXSW SYDNEY® 202420.5.2024 23:00:00 CEST | Press release

Also named as an endorsed Creative Experiential Partner for the 2024 event Sydney, May 20, 2024 (GLOBE NEWSWIRE) -- INVNT™, the Experiential Disrupter Agency, has today been announced as the sponsor and co-producer of the SXSW Sydney 2024 Discovery Stage after a successful collaboration at last year’s inaugural event. For the second consecutive year, INVNT will bring its world-class expertise in production and innovative brand storytelling and “Challenge Everything” ethos to SXSW Sydney, where it will continue its legacy of hosting, curating and presenting the Discovery Stage and activating across the event’s key pillars of Tech & Innovation, Music, Games and Screen. Featured within the SXSW Sydney Tech & Innovation Expo, the 2024 Discovery Stage will play host to inspiring innovation leaders who are redefining industry norms and will be a place to explore the latest developments in technology and meet startup founders who are poised to disrupt the status quo. As last year’s Discovery

Nokia Corporation: Repurchase of own shares on 20.05.202420.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 20 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 20.05.2024 Espoo, Finland – On 20 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL370,3933.56CEUX--BATE--AQEU--TQEX--Total370,3933.56 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM20.5.2024 20:15:00 CEST | Press release

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decadeand first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS s

HiddenA line styled icon from Orion Icon Library.Eye